Primary Aldosteronism and Drug Resistant Hypertension: A “Chicken-Egg” Story

Abstract

Drug-resistant arterial hypertension (RH) is a major risk factor for cardiovascular disease, often due to overlooked underlying causes. Identification of such causes poses significant clinical challenges. In this setting, primary aldosteronism (PA) is a frequent cause of RH and its prevalence in RH patients is likely higher than 20%.

The pathophysiological link between PA and the development and maintenance of RH involves target organ damage and the cellular and extracellular effects of aldosterone excess that promote pro-inflammatory and pro-fibrotic changes in the kidney and vasculature.

The feasibility of adrenal vein sampling in PA patients with RH, and the clinical benefit achieved by adrenalectomy, further emphasize the need to implement systematic screening for this common form of secondary hypertension in the management of a high-risk population as RH patients.

We herein review the current knowledge of the factors that contribute to the RH phenotype with a focus on PA and discuss the issues regarding the screening for PA in this setting and the therapeutic approaches (surgical and medical) aimed at resolving RH caused by PA.

Key words

primary aldosteronism - drug resistant hypertension - mineralocorticoid receptor antagonists

Publication History

Received: 31 January 2023
Received: 07 March 2023

Accepted: 27 March 2023

Accepted Manuscript online:
13 April 2023

Article published online:
31 May 2023

• References

• 1 Carey RM, Sakhuja S, Calhoun DA. et al. Prevalence of apparent treatment-resistant hypertension in the United States: Comparison of the 2008 and 2018 American Heart Association scientific statements on resistant hypertension. Hypertension 2019; 73: 424-431
• 2 Noubiap JJ, Nansseu JR, Nyaga UF. et al. Global prevalence of resistant hypertension: A meta-analysis of data from 3.2 million patients. Heart 2019; 105: 98-105
• 3 Daugherty SL, Powers JD, Magid DJ. et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642
• 4 Carey RM, Calhoun DA, Bakris GL. et al. Resistant hypertension: Detection, evaluation, and management a scientific statement from the American Heart Association. Hypertension 2018; 72: E53-E90
• 5 Williams B, Mancia G, Spiering W. et al. 2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension ESC/ESH task force for the management of arterial hypertension. J Hypertens 2018; 36: 2284-2309
• 6 Unger T, Borghi C, Charchar F. et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75: 1334-1357
• 7 Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC. Eur Heart J 2013; 34: 2159-2219
• 8 De La Sierra A, Segura J, Banegas JR. et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902
• 9 Danaietash P, Verweij P, Wang JG. et al. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertens 2022; 24: 804-813
• 10 Hayes P, Casey M, Glynn LG. et al. Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care. Br J Gen Pract 2018; 68: e394-e400
• 11 Azizi M, Sapoval M, Gosse P. et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 2015; 385: 1957-1965
• 12 Calhoun DA, Nishizaka MK, Zaman MA. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896
• 13 Rossi GP, Bisogni V, Rossitto G. et al. Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension. High Blood Press Cardiovasc Prev 2020; 27: 547-560
• 14 Rossi GP, Rossitto G, Amar L. et al. Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: The AVIS-2-RH study. Eur J Prev Cardiol 2022; 29: E85-E93
• 15 Connell JMC, Davies E.. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20
• 16 Gomez-Sanchez E, Gomez-Sanchez CE.. The multifaceted mineralocorticoid receptor. Compr Physiol 2014; 4: 965-994
• 17 Lenzini L, Caroccia B, Seccia TM. et al. Peptidergic G protein – coupled receptor regulation of adrenal function: Bench to bedside and back. Endocr Rev 2022; 1038-1050
• 18 Lenzini L, Prisco S, Caroccia B. et al. Saga of familial hyperaldosteronism yet a new channel. Hypertension 2018; 71: 1010-1014
• 19 Choi M, Scholl UI, Yue P. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
• 20 Scholl UI, Goh G, Stolting G. et al Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45: 1050-1054 [doi]
• 21 Azizan EA, Poulsen H, Tuluc P. et al Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055-1060 [doi]
• 22 Daniil G, Fernandes-Rosa FL, Chemin J. et al. CACNA1H mutations are associated with different forms of primary aldosteronism. EBioMedicine 2016; 13: 225-236
• 23 Scholl UI, Stölting G, Nelson-Williams C. et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 2015; 2015
• 24 Scholl UI, Stölting G, Schewe J. et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet 2018; 50: 349-354
• 25 Fernandes-Rosa FL, Daniil G, Orozco IJ. et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet 2018;
• 26 Beuschlein F, Boulkroun S, Osswald A. et al Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45: 440-444 444e1-2
• 27 Lenzini L, Rossitto G, Maiolino G. et al. A meta-analysis of somatic KCNJ5 K+ channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab 2015; 100: E1089-E1095
• 28 Manichaikul A, Rich SS, Allison MA. et al. KCNK3 variants are associated with hyperaldosteronism and hypertension. Hypertension. 2016; 68: 356-364
• 29 Dutta RK, Larsson M, Arnesen T. et al. X-chromosome variants are associated with aldosterone producing adenomas. Sci Rep 2021; 11: 1-8
• 30 Le Floch E, Cosentino T, Larsen CK. et al. Identification of risk loci for primary aldosteronism in genome-wide association studies. Nat Commun 2022; 13
• 31 Irvin MR, Sitlani CM, Floyd JS. et al. Genome-wide association study of apparent treatment-resistant hypertension in the CHARGE consortium: The CHARGE Pharmacogenetics Working Group. Am J Hypertens 2019; 32: 1146-1153
• 32 Buffolo F, Tetti M, Mulatero P. et al. Aldosterone as a mediator of cardiovascular damage. Hypertension 2022; 79: 1899-1911
• 33 Harvey AP, Montezano AC, Hood KY. et al. Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: The aldosterone-mineralocorticoid receptor-Nox1 axis. Life Sci 2017; 179: 110-119
• 34 Nagata D, Takahashi M, Sawai K. et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-171
• 35 Romagni P, Rossi F, Guerrini L. et al. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003; 166: 345-349
• 36 Xavier FE, Aras-López R, Arroyo-Villa I. et al. Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A 2 and prostacyclin. Br J Pharmacol 2008; 154: 1225-1235
• 37 Jaffe IZ, Tintut Y, Newfell BG. et al. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 2007; 27: 799-805
• 38 Gao JW, He WB, Xie CM. et al. Aldosterone enhances high phosphate–induced vascular calcification through inhibition of AMPK-mediated autophagy. J Cell Mol Med 2020; 24: 13648-13659
• 39 Koenig JB, Jaffe IZ.. Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: Novel mechanisms and clinical implications. Curr Hypertens Rep 2014; 16
• 40 Blasi ER, Rocha R, Rudolph AE. et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800
• 41 Rossi GP, Gioco F, Fassina A. et al. Normoaldosteronemic aldosterone-producing adenoma: Immunochemical characterization and diagnostic implications. J Hypertens 2015; 33: 2546-2549
• 42 Rossi GP, Barisa M, Belfiore A. et al The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010; 28: 1892-1899 [doi]
• 43 Wu CH, Yang YW, Hu YH. et al. Comparison of 24-h urinary aldosterone level and random urinary aldosterone-to-creatinine ratio in the diagnosis of primary aldosteronism. PLoS One 2013; 8: 4-9
• 44 Funder J.. Primary aldosteronism. Trends Cardiovasc Med 2022; 32: 228-233
• 45 Hung CS, Ho YL, Chang YY. et al. Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. Sci World J 2013; 2013
• 46 Rossi GP, Seccia TM, Palumbo G. et al. Within-patient reproducibility of the aldosterone: Renin ratio in primary aldosteronism. Hypertension 2010; 55: 83-89
• 47 Jaffe G, Gray Z, Krishnan G. et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 650-659
• 48 Rossi GP.. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011; 7: 485-495
• 49 Beeftink MMA, Van Der Sande NGC, Bots ML. et al. Safety of temporary discontinuation of antihypertensive medication in patients with difficult-to-control hypertension. Hypertension 2017; 69: 927-932
• 50 Rossitto G. et al. Subtyping of primary aldosteronism in the AVIS-2 study: Assessment of selectivity and lateralization. J Clin Endocrinol Metab 2020; 2044: 2042-2052
• 51 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. lancet Diabetes Endocrinol 2018; 6: 51-59
• 52 Leung AA, Symonds CJ, Hundemer GL. et al. Performance of confirmatory tests for diagnosing primary aldosteronism: A systematic review and meta-analysis. Hypertension 2022; 79: 1835-1844
• 53 Zhu R, Shagjaa T, Rossitto G. et al. Exclusion tests in unilateral primary aldosteronism (ExcluPA) study. J Clin Endocrinol Metab 2022; 108: 496-506
• 54 Irony I, Kater CE, Biglieri EG. et al. Correctable subsets of primary aldosteronism primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576-582
• 55 Douma S, Petidis K, Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study. Lancet 2008; 371: 122-138
• 56 Parasiliti-Caprino M, Lopez C, Prencipe N. et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens 2020; 38: 1841-1848
• 57 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088
• 58 Manosroi W, Atthakomol P.. High body fat percentage is associated with primary aldosteronism: A cross-sectional study. BMC Endocr Disord 2020; 20
• 59 Ahmed AH, Gordon RD, Taylor PJ. et al. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?. J Clin Endocrinol Metab 2011; 96: 340-346
• 60 Puar TH, Khoo CM, Tan CJ. et al. 11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: A prospective clinical trial. J Hypertens 2022; 40: 1179-1188
• 61 Isojärvi J, Viukari M, Pörsti I. et al. Lateralization in 11C-metomidate PET and outcome of adrenalectomy in primary aldosteronism. Endocrinol Diabetes Metab 2022; 5: 1-8
• 62 Soinio M, Luukkonen A, Seppänen M. et al. Functional imaging with 11 C-metomidate PET for subtype diagnosis in primary aldosteronism. 2020
• 63 O’Shea PM, O’Donoghue D, Bashari W. et al. 11C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol (Oxf) 2019; 90: 670-679
• 64 Burton TJ, Mackenzie IS, Balan K. et al. Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab 2012; 97: 100-109
• 65 Hennings J, Sundin A, Hägg A. et al. 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbeck’s Arch Surg 2010; 395: 963-967
• 66 Ding J, Tong A, Zhang Y. et al. Functional characterization of adrenocortical masses in nononcologic patients using 68Ga-pentixafor. J Nucl Med 2022; 63: 368-375
• 67 Heinze B, Fuss CT, Mulatero P. et al. Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension 2018; 71: 317-325
• 68 Wu X, Senanayake R, Goodchild E. et al. [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: A prospective, within-patient trial. Nat Med 2023;
• 69 Lu CC, Chen CJ, Peng KY. et al. Predicting treatment response in primary aldosteronism using 11C-metomidate positron emission tomography. Clin Nucl Med 2022; 47: 936-942
• 70 Dekkers T, Prejbisz A, Kool LJS. et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: An outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol 2016; 4: 739-746
• 71 Funder JW, Rossi GP.. Adrenal vein sampling versus CT scanning in primary aldosteronism. Lancet Diabetes Endocrinol 2016; 4: 886
• 72 Rossi GP, Funder JW.. Adrenal vein sampling is the preferred method to select patients with primary aldosteronism for adrenalectomy: Pro side of the argument. Hypertension 2018; 71: 5-9
• 73 Rossi GP, Crimì F, Rossitto G. et al. Feasibility of imaging-guided adrenalectomy in young patients with primary aldosteronism. Hypertension 2022; 79: 187-195
• 74 Lee J, Kang B, Ha J. et al. Clinical outcomes of primary aldosteronism based on lateralization index and contralateral suppression index after adrenal venous sampling in real-world practice: a retrospective cohort study. BMC Endocr Disord 2020; 20
• 75 Dobrowolski P, Kołodziejczyk-Kruk S, Warchoł-Celińska E. et al. Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. J Clin Sleep Med 2021; 17: 629-637
• 76 Rossi GP, Bisogni V, Bacca AV. et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens 2020; 5
• 77 Conroy PC, Hernandez S, Graves CE. et al. Screening for primary aldosteronism is underutilized in patients with obstructive sleep apnea. Am J Med 2022; 135: 60-66
• 78 Stavropoulos K, Imprialos KP, Patoulias D. et al. Impact of primary aldosteronism in resistant hypertension. Curr Hypertens Rep 2022; 24: 285-294
• 79 Torresan F, Giacomo R, Bisogni V. et al. Resolution of drug-resistant hypertension by adrenal vein sampling-guided adrenalectomy: A proof-of-concept study. Clin Sci 2020; 134: 1265-1278
• 80 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
• 81 Bioletto F, Bollati M, Lopez C. et al. Primary aldosteronism and resistant hypertension: A Pathophysiological Insight. Int J Mol Sci 2022; 23
• 82 Williams B, Macdonald TM, Morant S. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-2068
• 83 Parthasarathy HK, Alhashmi K, McMahon AD. et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens 2010; 28: 170-177
• 84 Maeoka Y, Su XT, Wang WH. et al. Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone. Hypertension 2022; 79: 1423-1434
• 85 Edwards NC, Steeds RP, Stewart PM. et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. A randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512
• 86 Pitt B, Reichek N, Willenbrock R. et al. effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838
• 87 Galceran I, Vázquez S, Crespo M. et al. Hypertensive mediated organ damage evolution in resistant hypertension patients after adding spironolactone. Nefrologia 2022;
• 88 Aryal SR, Siddiqui M, Sharifov OF. et al. Spironolactone reduces aortic stiffness in patients with resistant hypertension independent of blood pressure change. J Am Heart Assoc 2021; 10
• 89 Duggan S.. Esaxerenone: First global approval. Drugs 2019; 79: 477-481
• 90 Bakris GL, Agarwal R, Anker SD. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383: 2219-2229
• 91 Agarwal R, Filippatos G, Pitt B. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484A
• 92 Freeman MW, Halvorsen Y-D, Marshall W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 2022;
• 93 Schlaich MP, Bellet M, Weber MA. et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): A multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022;
• 94 Rossi GP, Ganzaroli C, Cesari M. et al. Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. 2003
• 95 Liu Y, Zhu B, Zhu L. et al. Thirty-six-month results of laparoscopic-based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral aldosterone-producing adenoma. J Clin Hypertens 2021; 23: 946-953
• 96 Liu Y, Gao C.. Reply. J Clin Hypertens 2022; 24: 206-208
• 97 Schiavone D, Iacobone M, Rossi GP.. Letter to editor on “Thirty-six-month results of laparoscopic-based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral aldosterone-producing Adenoma”. J Clin Hypertens 2022; 24: 204-205
• 98 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916